HER2+ Breast Cancer | Specialty

Changing Treatment Landscape in Metastatic Breast Cancer

August 5th 2014

Extended Adjuvant Neratinib Improves DFS in Phase III Breast Cancer Study

July 23rd 2014

Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly extended improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab

Dr. Tripathy on Decision-Making for Sequencing Therapies for HER2-Positive MBC

July 18th 2014

Debu Tripathy, MD, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.

Risk of Recurrence Low in Small, HER2-Positive Breast Tumors

July 15th 2014

Patients with small, node-negative, HER2-positive breast cancer tumors had a low risk of invasive recurrence after 5 years

T-DM1 Poised to Set New Standard in HER2-Positive Metastatic Breast Cancer

July 14th 2014

The antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) will have an impact on the entire spectrum of care for patients with metastatic HER2-positive breast cancer, resulting in a greater emphasis on patient selection protocols and testing.

Trastuzumab-Associated Cardiac Events Reversible, Outweighed by Benefits

July 14th 2014

Cardiac events associated with trastuzumab are mostly reversible and outweighed by significant extensions in OS and PFS for patients with HER2-positive breast cancer, according to analyses from several clinical trials exploring the drug.

Dr. Brufsky on Trastuzumab and Eribulin for HER2+ Metastatic Breast Cancer

July 11th 2014

Adam M. Brufsky, MD, PhD, discusses the effect of prior trastuzumab on eribulin mesylate in combination with trastuzumab as first-line treatment for HER2-positive locally recurrent or metastatic breast cancer.

Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast Cancer

June 24th 2014

Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.

Charles M. Perou, PhD, Discusses Genomic Signatures and Dual HER2-Targeting in Breast Cancer

June 13th 2014

Charles M. Perou, PhD, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting that analyzed gene expression signatures in patients with HER2-positive breast cancer treated with weekly paclitaxel and trastuzumab with or without lapatinib.

Negative ALTTO Results Reverberate for Lapatinib, Novel Clinical Trials

June 1st 2014

A dual HER2-blockade strategy that added lapatinib to trastuzumab for the adjuvant treatment of women with early breast cancer failed to demonstrate a significant improvement in DFS over the standard therapy with trastuzumab alone.

Update on Novel Drug Targets in Metastatic Breast Cancer

May 16th 2014

More recently, researchers seek to understand the mechanisms related to tumor dissemination in hopes of therapeutically targeting this process.

New Options for Low-Risk, HER2-Positive Tumors Featured in Research Overview

May 7th 2014

Fresh insights into outcomes for patients with low-risk, HER2-positive breast cancer suggest that adjuvant chemotherapy regimens with or without trastuzumab (Herceptin) should be considered as options for managing this growing population

Dr. Tripathy on the Treatment of Patients With MBC

April 29th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses advances in the treatment of metastatic breast cancer.

Dr. Verma on Targeting HER2 in Early-Stage Breast Cancer

April 14th 2014

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in early-stage breast cancer.

Experts Support Broader Pertuzumab Use in HER2-Positive Breast Cancer

April 14th 2014

The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.

Breast Cancer Patients Fare Worse When Adjuvant Chemotherapy Is Delayed

April 4th 2014

Breast cancer patients whose chemotherapy is initiated >60 days following surgery experience worse survival outcomes

Breast Cancer Expert Offers Views on Promising Strategies

April 1st 2014

Now that targeted therapies are available for the treatment of various subtypes of breast cancer, and many novel agents are under investigation, it is important for the oncology community to follow the latest advancements to give patients the best available options.

Antibody-Drug Conjugates and T-DM1

March 21st 2014

Human epidermal growth factor receptor 2 (HER2)-positive disease accounts for 20% to 25% of breast cancers, as represented by amplification of the HER2 gene and/or HER2 protein overexpression

Common Adverse Effects of Anti-HER2 Therapies and Practical Management Recommendations

March 12th 2014

The benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.

Trastuzumab/Eribulin Combo Safe and Effective in HER2-Positive Breast Cancer

March 10th 2014

The first-line combination of trastuzumab and eribulin mesylate demonstrated an ORR of 71.2% with a median PFS of 11.6 months in patients with HER2-positive advanced breast cancer.